| Year |
Citation |
Score |
| 2020 |
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, et al. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism. PMID 33340032 DOI: 10.1038/s42255-020-00335-x |
0.333 |
|
| 2020 |
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism. PMID 33230295 DOI: 10.1038/s42255-020-00313-3 |
0.387 |
|
| 2017 |
Lin Y, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Gilbert LIR, Bosajou A, Sun D, Marszalek J, Sun Y, McMurray JS, Mandal PK, et al. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A39 |
0.508 |
|
| 2016 |
Leonard PG, Satani N, Maxwell D, Lin YH, Hammoudi N, Peng Z, Pisaneschi F, Link TM, Lee GR, Sun D, Prasad BA, Di Francesco ME, Czako B, Asara JM, Wang YA, et al. SF2312 is a natural phosphonate inhibitor of enolase. Nature Chemical Biology. PMID 27723749 DOI: 10.1038/Nchembio.2195 |
0.474 |
|
| 2016 |
Lin Y, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Lee G, Sun D, Marszalek J, Sun Y, McMurray J, Mandal P, Di Francesco M, et al. POMHEX, a cell-permeable enolase inhibitor for collateral lethality targeting of ENO1-deleted glioblastoma European Journal of Cancer. 69: S124. DOI: 10.1016/S0959-8049(16)32968-9 |
0.456 |
|
| 2015 |
Lin Y, Marszalek J, Sun Y, Hammoudi N, Leonard P, Maxwell D, Satani N, Zhang P, Link T, Lee G, Francesco MED, Czako B, Want AY, DePinho RA, Muller FL. Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C183 |
0.53 |
|
| 2014 |
Peng Z, Maxwell D, Sun D, Ying Y, Schuber PT, Bhanu Prasad BA, Gelovani J, Yung WK, Bornmann WG. Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies. Tetrahedron. 70: 984-990. PMID 25110363 DOI: 10.1016/J.Tet.2013.11.092 |
0.396 |
|
| 2014 |
Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, et al. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorganic & Medicinal Chemistry. 22: 1450-8. PMID 24457091 DOI: 10.1016/J.Bmc.2013.12.048 |
0.406 |
|
| 2014 |
Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Pal A, Wang S, Balatoni J, Ghosh P, Lim ST, Volgin A, Shavrin A, Alauddin MM, Gelovani JG, Bornmann WG. Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level. Bioorganic & Medicinal Chemistry. 22: 623-32. PMID 24280068 DOI: 10.1016/J.Bmc.2013.10.040 |
0.385 |
|
| 2014 |
Zuo M, Maxwell D, Prasad BAB, Peng Z, Bornmann W, Javle MM. Abstract 5361: Development of targeted inhibitors against RecQ1 helicase Cancer Research. 74: 5361-5361. DOI: 10.1158/1538-7445.Am2014-5361 |
0.507 |
|
| 2014 |
Bornmann WG, Peng Z, Maxwell D, Sun D, Bhanu BA, Talpaz M, Donato N, Levitzki A. Abstract 2698: Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I) Cancer Research. 74: 2698-2698. DOI: 10.1158/1538-7445.Am2014-2698 |
0.478 |
|
| 2014 |
Chiao PJ, Zhuang Z, Xia Q, Schuber PT, Sun D, Peng Z, Maxwell DS, Bornmann WG. Abstract 1727: Development of novel TAK1 inhibitors for pancreatic cancer Cancer Research. 74: 1727-1727. DOI: 10.1158/1538-7445.Am2014-1727 |
0.497 |
|
| 2013 |
Vanderslice P, Biediger RJ, Woodside DG, Brown WS, Khounlo S, Warier ND, Gundlach CW, Caivano AR, Bornmann WG, Maxwell DS, McIntyre BW, Willerson JT, Dixon RA. Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion. The Journal of Biological Chemistry. 288: 19414-28. PMID 23703610 DOI: 10.1074/Jbc.M113.479634 |
0.356 |
|
| 2013 |
Arumugam T, Ramachandran V, Sun D, Peng Z, Pal A, Maxwell DS, Bornmann WG, Logsdon CD. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Molecular Cancer Therapeutics. 12: 654-62. PMID 23303403 DOI: 10.1158/1535-7163.Mct-12-0771 |
0.341 |
|
| 2013 |
Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorganic & Medicinal Chemistry. 21: 932-9. PMID 23294827 DOI: 10.1016/J.Bmc.2012.12.008 |
0.36 |
|
| 2013 |
Maxwell DS, Sun D, Peng Z, Qi W, McConkey D, Abbruzzese JL, Bornmann WG. Abstract B101: Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B101 |
0.483 |
|
| 2012 |
Zhou Y, Tozzi F, Xia L, Fan F, Lu J, Maxwell D, Gao G, Bornmann W, Weihua Z, Ellis LM. Abstract B64: Development of a novel strategy to overcome drug resistance by targeting ATP citrate lyase and de novo lipogenesis in colorectal cancer cells Clinical Cancer Research. 18: B64-B64. DOI: 10.1158/1078-0432.Mechres-B64 |
0.448 |
|
| 2011 |
Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W. Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorganic & Medicinal Chemistry. 19: 7194-204. PMID 22036213 DOI: 10.1016/J.Bmc.2011.09.057 |
0.471 |
|
| 2011 |
Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination Cellular Signalling. 23: 2076-2085. PMID 21855629 DOI: 10.1016/J.Cellsig.2011.08.002 |
0.477 |
|
| 2011 |
Lan PV, Tamayo AT, Li C, Sun D, Pal A, Peng Z, Maxwell D, Ford RJ, Bornmann WG. Abstract A129: Development of turmerax therapeutic compounds in aggressive, refractory B cell non-Hodgkin's lymphoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A129 |
0.447 |
|
| 2011 |
Kupferman ME, Lee J, Sun D, Peng Z, Maxwell DS, Bornmann WG. Abstract A122: Therapeutic modulation of Trkb in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A122 |
0.528 |
|
| 2010 |
Xie X, Bartholomeusz C, Maxwell D, Peng Z, Kazansky A, Bornmann W, Ueno N. Abstract P6-15-20: Development of PEA-15-Based Therapy in Breast Cancer in a Preclinical Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-15-20 |
0.44 |
|
| 2009 |
Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Research. 69: 3910-7. PMID 19383925 DOI: 10.1158/0008-5472.Can-08-0034 |
0.505 |
|
| 2008 |
le Roux L, Volgin A, Maxwell D, Ishihara K, Gelovani J, Schellingerhout D. Optimizing imaging of three-dimensional multicellular tumor spheroids with fluorescent reporter proteins using confocal microscopy. Molecular Imaging. 7: 214-21. PMID 19123991 |
0.267 |
|
| 2008 |
Peterson LF, Sun H, Bornmann W, Peng Z, Maxwell D, Donato N, Talpaz M. Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors Blood. 112: 3212-3212. DOI: 10.1182/Blood.V112.11.3212.3212 |
0.497 |
|
| 2008 |
Roux LGL, Maxwell D, Schellingerhout D, Volgin A, Gelovani J. A novel software algorithm for the quantitative assessment of fluorescent reporter proteins in multi-cellular tumor spheroids Microscopy and Microanalysis. 14: 722-723. DOI: 10.1017/S1431927608085425 |
0.351 |
|
| 2008 |
Roux LGL, Schellingerhout D, Volgin A, Maxwell D, Ishihara K, Gelovani J. Optimizing Imaging of 3D Multicellular Tumor Spheroids with Fluorescent Reporter Proteins using Confocal Microscopy Microscopy and Microanalysis. 14: 734-735. DOI: 10.1017/S1431927608084559 |
0.354 |
|
| 2008 |
Volgin A, LeRoux L, Maxwell D, Schellingerhout D, Thitai-Kumar A, He Y, Gelovani J, Schwartz DL. In Vitro 3D Modeling of Host Organ-specific Whole Tumor Responses to Radiation International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.566 |
0.341 |
|
| 2007 |
Bommarius B, Maxwell D, Swimm A, Leung S, Corbett A, Bornmann W, Kalman D. Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation. Molecular Microbiology. 63: 1748-68. PMID 17367393 DOI: 10.1111/J.1365-2958.2007.05626.X |
0.404 |
|
| 2007 |
Faderl S, Bornmann W, Maxwell D, Peng Z, Van Q, Liu Z, Verstovsek S, Ferrajoli A, Kantarjian HM, Estrov Z. Molecular targeting in acute myeloid leukemia (AML) therapy: APcK110 is a new inhibitor of c-Kit activity in AML blasts Journal of Clinical Oncology. 25: 7019-7019. DOI: 10.1200/Jco.2007.25.18_Suppl.7019 |
0.502 |
|
| 2007 |
Kapuria V, Bartholomeusz G, Kong L, Bornmann W, Peng Z, Pal A, Maxwell D, Talpaz M, Donato N. A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling. Blood. 110: 1556-1556. DOI: 10.1182/Blood.V110.11.1556.1556 |
0.498 |
|
| 2007 |
Donato N, Kapuria V, Sun H, Maxwell D, Bartholomeusz G, Bornmann W, Peng Z, Pal A, Talpaz M. Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation. Blood. 110: 1003-1003. DOI: 10.1182/Blood.V110.11.1003.1003 |
0.503 |
|
| 2006 |
Pal A, Glekas A, Doubrovin M, Balatoni J, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG. Molecular Imaging of EGFR kinase activity in tumors with 124 I-Labeled small molecular tracer and positron emission tomography Molecular Imaging and Biology. 8: 262-277. PMID 16897320 DOI: 10.1007/S11307-006-0049-0 |
0.471 |
|
| 2006 |
Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Molecular Cancer Therapeutics. 5: 1325-34. PMID 16731766 DOI: 10.1158/1535-7163.Mct-05-0494 |
0.358 |
|
| 2006 |
O'Brian CA, Chu F, Bornmann WG, Maxwell DS. Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? Expert Review of Anticancer Therapy. 6: 175-86. PMID 16445370 DOI: 10.1586/14737140.6.2.175 |
0.392 |
|
| 2006 |
Maxwell DS, Pal A, Peng Z, Shavrin A, Faderl S, Harris D, Van Q, Liu Z, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM, Estrov Z, Bornmann WG. Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia. Blood. 108: 1906-1906. DOI: 10.1182/Blood.V108.11.1906.1906 |
0.48 |
|
| 2006 |
Faderl S, Bornmann W, Maxwell D, Pal A, Peng Z, Shavrin A, Harris D, Van Q, Zhiming L, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM, Estrov Z. APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells. Blood. 108: 153-153. DOI: 10.1182/Blood.V108.11.153.153 |
0.494 |
|
| 2006 |
Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG. Erratum: Molecular Imaging of EGFR Kinase Activity in Tumors with 124I-Labeled Small Molecular Tracer and Positron Emission Tomography (Mol Imaging Biol (2006) vol. 8 (5) (262-277) 10.1007/s11307-006-0049-0)) Molecular Imaging and Biology. 8. DOI: 10.1007/S11307-006-0067-Y |
0.405 |
|
| 2005 |
Zhang M, Wang L, Maxwell D. Subdivision approach to target-constrained conformational searching. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 3: 2607-10. PMID 17282772 DOI: 10.1109/IEMBS.2005.1617003 |
0.228 |
|
| 1996 |
Jorgensen WL, Maxwell DS, Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids Journal of the American Chemical Society. 118: 11225-11236. DOI: 10.1021/Ja9621760 |
0.42 |
|
| 1995 |
Maxwell DS, Tirado-Rives J, Jorgensen WL. A comprehensive study of the rotational energy profiles of organic systems by ab initio MO theory, forming a basis for peptide torsional parameters Journal of Computational Chemistry. 16: 984-1010. DOI: 10.1002/Jcc.540160807 |
0.426 |
|
| 1993 |
Tirado-Rives J, Maxwell DS, Jorgensen WL. Molecular dynamics and Monte Carlo simulations favor the a-helical form for alanine-based peptides in water Journal of the American Chemical Society. 115: 11590-11593. DOI: 10.1021/Ja00077A066 |
0.406 |
|
| Show low-probability matches. |